A detailed history of Woodline Partners LP transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Woodline Partners LP holds 779,956 shares of ARCT stock, worth $12.1 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
779,956
Previous 754,023 3.44%
Holding current value
$12.1 Million
Previous $18.4 Million 1.41%
% of portfolio
0.16%
Previous 0.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.08 - $25.38 $468,868 - $658,179
25,933 Added 3.44%
779,956 $18.1 Million
Q2 2024

Aug 14, 2024

SELL
$24.35 - $44.39 $3.9 Million - $7.12 Million
-160,341 Reduced 17.54%
754,023 $18.4 Million
Q1 2024

May 15, 2024

SELL
$31.23 - $42.99 $4.85 Million - $6.68 Million
-155,450 Reduced 14.53%
914,364 $30.9 Million
Q2 2023

Aug 14, 2023

BUY
$23.94 - $32.36 $6.02 Million - $8.13 Million
251,376 Added 30.71%
1,069,814 $30.7 Million
Q1 2023

May 15, 2023

BUY
$14.72 - $23.97 $973,095 - $1.58 Million
66,107 Added 8.79%
818,438 $19.6 Million
Q4 2022

Feb 14, 2023

SELL
$14.14 - $23.06 $1.77 Million - $2.89 Million
-125,193 Reduced 14.27%
752,331 $12.8 Million
Q3 2022

Nov 14, 2022

BUY
$13.05 - $22.13 $11.5 Million - $19.4 Million
877,524 New
877,524 $13 Million
Q2 2021

Aug 16, 2021

SELL
$25.79 - $42.11 $217,719 - $355,492
-8,442 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$38.75 - $86.92 $327,127 - $733,778
8,442 New
8,442 $349,000
Q4 2020

Feb 16, 2021

SELL
$34.61 - $123.66 $1.35 Million - $4.82 Million
-39,016 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$37.49 - $63.19 $4.09 Million - $6.89 Million
-109,067 Reduced 73.65%
39,016 $1.67 Million
Q2 2020

Aug 14, 2020

BUY
$12.66 - $58.27 $1.87 Million - $8.63 Million
148,083 New
148,083 $6.92 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $411M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.